Tag: IN.PACT Admiral

stellarex

Latest data from Philips reinforces the safety profile of Stellarex low-dose...

A new pooled analysis of patient-level data from Philips demonstrates the “strong safety profile” of the its Stellarex drug-coated balloon (DCB) in above-the-knee studies,...

IN.PACT SFA five-year outcomes show sustained benefits of drug-coated balloon in...

The IN.PACT SFA trial’s co-principal investigator John Laird, from the Adventist Heart and Vascular Institute in St. Helena, USA, has presented the five-year outcomes...

IN.PACT SFA Trial five-year data and Total IN.PACT All-Subjects analysis presented...

  The five-year and final results from the pivotal IN.PACT SFA Trial and one-year all-subjects results from the Total IN.PACT Pooled Analysis of the IN.PACT...
Purple drug-coated balloon in an s shape

IN.PACT Admiral DCB receives FDA approval for long SFA lesions

Medtronic has announced that it has received US Food and Drug Administration (FDA) approval for the IN.PACT Admiral drug-coated balloon (DCB) to treat long superficial...

US FDA grants Medtronic investigational device exemption for new In.Pact Admiral...

Medtronic has received an investigational device exemption (IDE) from the US Food and Drug Administration (FDA) to initiate a study of the In.Pact Admiral...

Three-year IN.PACT SFA trial results demonstrate durability, safety and efficacy for...

Medtronic reinforced the durability, consistency, and safety of the IN.PACT Admiral drug-coated balloon in patients with peripheral arterial disease with new data presented in a...